Share

May 30, 2017; 88 (22) Editorial

Autologous hematopoietic stem cell transplantation for MS

Safer than previously thought

Joachim Burman, Robert J. Fox
First published April 28, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003995
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
226

Share

Article Information

vol. 88 no. 22 2072-2073
DOI: 
https://doi.org/10.1212/WNL.0000000000003995
PubMed: 
28455384
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 28, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Joachim Burman, MD, PhD and
    2. Robert J. Fox, MD, FAAN
  1. Joachim Burman, MD, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. MS research fund 2. Swedish Society for Medical Research 3. Swedish Society of Medicine

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Robert J. Fox, MD, FAAN
    3. Scientific Advisory Boards:

    1. Biogen Idec, Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board, Neurology Editorial Board, Multiple Sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. Multiple Sclerosis and Related Disorders, Demos Medical, 2013

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Actelion, Biogen, Genentech, Novartis, Teva.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research grant from Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society, RC 1004-A-5, 2010- 2013; RG 4778-A-6, 2013-2018; NIH 1U01NS082329-01A1, 2013- 2018; Consortium of MS Centers

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neuroscience (J.B.), Uppsala University, Sweden; and Mellen Center for Multiple Sclerosis (R.J.F.), Neurological Institute, Cleveland Clinic, OH.
  1. Correspondence to Dr. Burman: joachim.burman{at}neuro.uu.se
View Full Text

Article usage

Article usage: April 2017 to April 2020

AbstractFullPdfSource
Apr 2017254011Highwire
May 20179352583Highwire
Jun 20173103131Highwire
Jul 2017861023Highwire
Aug 2017391316Highwire
Sep 20174054Highwire
Oct 20176253Highwire
Nov 201733505Highwire
Dec 20174222Highwire
Jan 20183332Highwire
Feb 20182621Highwire
Mar 20184864Highwire
Apr 20182821Highwire
May 20184346Highwire
Jun 20186811Highwire
Jul 20183823Highwire
Aug 20182931Highwire
Sep 20181824Highwire
Oct 20184922Highwire
Nov 20183520Highwire
Dec 20182833Highwire
Jan 20193702Highwire
Feb 20191400Highwire
Mar 20192431Highwire
Apr 20194065Highwire
May 20194420Highwire
Jun 20191821Highwire
Jul 20192021Highwire
Aug 20191334Highwire
Sep 20191612Highwire
Oct 20191921Highwire
Nov 20194922Highwire
Dec 20192000Highwire
Jan 20201200Highwire
Feb 20201521Highwire
Mar 20201600Highwire
Apr 2020500Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me